News
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
GAITHERSBURG, Md., Aug. 26, 2024 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
GAITHERSBURG, Md., Aug. 14, 2024 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT),...
Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
GAITHERSBURG, Md., July 19, 2024 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT),...
Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
Current CFO, Michael Vander Hoek, transitions to full-time Vice President, RegulatoryGAITHERSBURG, Md., June 18, 2024 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company...
Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
GAITHERSBURG, Md., May 22, 2024 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that...
Shuttle Pharma Provides First Quarter 2024 Corporate Update
GAITHERSBURG, Md., May 14, 2024 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today...
Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1×1 Meetings on Thursday, May 2, 2024
GAITHERSBURG, Md., April 23, 2024 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy ("RT"), today announced...
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024
Webcasted presentation to take place at 3:10pm ETGAITHERSBURG, Md., April 03, 2024 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated...
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
GAITHERSBURG, Md., March 21, 2024 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT),...
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024
Webcast presentation to take place at 11:25am ETROCKVILLE, Md., March 05, 2024 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated...